Pernix Therapeutics

Therapy Session 4

Therapy Session 4 (Photo credit: Colorblind Seb)

PTX : NYSE MKT : US$6.26
BUY 
Target: US$14.00 

COMPANY DESCRIPTION:
Pernix Therapeutics Holdings is a specialty pharmaceutical company that develops and manufactures generic and branded prescription and OTC
products, with particular emphasis on pediatrics. PTX is focused in the areas of allergy, upper respiratory, antibiotics and dermatology. PTX is headquartered in The Woodlands, TX.

Pernix announced that it has completed the acquisition of Somaxon Pharmaceuticals (key branded product Silenor for insomnia). The deal adds a nice low-risk, on-market branded product that PTX will give its sales force to reinvigorate sales (similar to Cedax), with also hopes of OTC potential down the road.

With the deal now closed, we would expect management to turn its attention back to more business development opportunities, which should continue to drive P&L upside. We should get more color here in two weeks (March 18), when PTX reports Q4 earnings.

Reiterate BUY rating and $14 target.
Model update – we forecast $0.11 accretion on our 2013 EPS We have updated our model for the closing of the Somaxon deal – we estimate ~$0.11 of accretion on 2013E EPS (and beyond). PTX gave preliminary guidance of $10-15 million in revenue add and $5-10 million in EBITDA for the first year post closing. We have also increased shares outstanding, which did end up near the high end of possible outcomes (3.665 million) given the lower stock price. Our new EPS estimates from 2013-2016 are now $0.39, $0.69, $1.06 and $1.61. That said, PTX is reporting Q4 EPS on Monday, March 18 (two weeks) where we would expect a fuller update around business trends and a chance to revisit our model and assumptions.
Valuation
Our $14 price target is derived from an equal-weighted ~20.5x P/E and ~7.5x EV/EBITDA multiple applied to our 2014 forecasts. PTX currently
trades at 9.1x P/E on our 2014 forecasts.

Bank of Nova Scotia

English: View of a ScotiaBank facade in Amhers...

English: View of a ScotiaBank facade in Amherst, Nova Scotia. This structure was erected in 1907. (Photo credit: Wikipedia)

BNS : TSX : C$61.32
BNS : NYSE
BUY 
Target: C$69.00

COMPANY DESCRIPTION:
Scotiabank is one of North America’s premier financial institutions, and Canada’s most international bank. With over 80,000 employees, Scotiabank Group and its affiliates serve over 19 million customers in more than 55 countries around the world. Scotiabank offers a diverse range of products and services including personal, commercial, corporate and investment banking.

Q1/13 core cash EPS was $1.27 (up 12% YoY) versus our estimate and consensus of $1.25. Revenue growth was better than expected, and PCLs came in lower than forecasted. The bank raised the quarterly dividend to $0.60 (5% QoQ and 9% YoY), higher than our estimate of $0.59.
International earnings were up 12% YoY, reflecting very strong operating leverage. Expense growth checked back to 15.5% YoY (0% QoQ) from the very high levels seen in 2012 (21% in full year 2012), resulting in operating leverage of 5.5%. Management indicated that the YoY increase in expenses largely related to acquisitions.

While we do not expect the bank to deliver mid-single-digit operating leverage in International, given the investment spending in 2012, we
do expect BNS to deliver 2-3% operating leverage in the segment in 2013. Importantly, commercial loan growth recovered after two consecutive quarters of disappointing QoQ growth.
Domestic P&C earnings were up 21% YoY on 13.3% YoY revenue growth and operating leverage of 1.2% (expense growth of 12.1% YoY). We were looking for earnings growth of 19%. Better than expected results relate to the ING Direct deal which added $45 million to earnings versus our estimate of $35-40 million. As Scotia functions with a significant funding gap in Canada, to the extent that the bank uses the lower cost retail deposits from ING to replace wholesale funding, the bank can quickly improve funding costs. At $45 million in earnings in the quarter, the bank is already near the $190 million run rate discussed at the time of the deal.
Over the last five years, the bank’s better earnings stability and momentum has earned Scotia an average premium of 5-7%. On our estimates, the stock currently trades at a 6% premium to the group. For the reasons outlined below, we set our target price on BNS based on the stock trading at a 7% premium (versus RY at a 6% premium). Our target P/E premium drives a target P/E of 12.3x applied against our 2014E EPS and a target price of C$69.00 (up from C$67.00).

Mylan : 4Q BRINGS UPSIDE AND THE MUCH ANTICIPATED DEAL

I Am Fluent In Three Languages ...item 1.. For...

I Am Fluent In Three Languages …item 1.. For-Profit Colleges Pay Executives Based On Profit (07/27/2012 ) …item 2.. RACE TO THE BOTTOM (Thursday, July 5, 2012) …item 3.. Senator Harkin’s Report: (JULY 29, 2012) … (Photo credit: marsmet523)

MYL : NASDAQ : US$28.57
BUY 
Target: US$33.00

COMPANY DESCRIPTION:
Mylan, Inc. (MYL) engages in the global development, marketing and producing of generic and brand pharmaceutical products. It operates two segments, Generics and Specialty, with branded drugs such as EpiPen Auto-Injector, Performist Inhalation Solution, and antiretroviral (ARV) drugs. It is headquartered in Canonsburg, Pennsylvania.

MYL’s 4Q results and 2013 guidance brought upside and raised guidance as expected. However, focus will be on the $1.6 billion announced Agila
deal.

Agila brings an attractive injectables platform and moderate accretion though, like many, we were surprised at the limited financial disclosure which will leave lingering questions and a wider range on pro forma Street EPS. Overall, we’re raising standalone EPS and increasing our target to $33.
 4Q and 2013 outlook largely as expected. 4Q brought a penny of costdriven upside while 2013 guidance largely straddled consensus with
revenue lowered and EPS raised (EMEA a positive surprise).
 Agila is 5-7% accretive in 2014-16 on our analysis. 2014 pro forma EPS will be the primary focus and our $3.32 is driven by 3% core upside and 5% deal accretion.
 Where do we go from here? Raised guidance and major deal announcement were the two primary catalysts we were looking for. Focus will now shift to 2014 with catalysts and EPS upside the primary drivers for both MYL and ACT. Assuming a modest upward stock move in MYL, valuation would be ~ in line with ACT (on our 2014 pro forma EPS) – we see upside in both but all else equal more near-term stock moving catalysts in ACT.
 We are raising our target to $33. Our raise reflects both higher 2014 standalone EPS (+3%) and accretion (+5%) though we for now leave
Agila out of published EPS. Our PT is based equally on 2014E P/E and EV/EBITDA and implies a 10x multiple on pro forma 2014E EPS.

Deere Q 1

John Deere 2130 Tractor

John Deere 2130 Tractor (Photo credit: Odalaigh)

DE : NYSE :

US$90.68
The  Big Green Profit Machine.

Deere saw a 22% increase in its Q1 earnings, driven by better sales in North America. Deere reported a profit of $649.7 million, or $1.65 a share, versus a year-earlier profit of $532.9 million, or $1.30 a share. Total revenue, which includes Deere’s finance unit, grew 10% to $7.42 billion.

Analysts had forecast earnings of $1.40 a share on $6.72 billion in  total revenue.

The company’s overall equipment sales in the U.S. and Canada, including construction and forestry equipment, rose 18% during the first quarter from a year earlier. The company now expects to earn $3.3 billion in profit this year, implying earnings per share of $8.45. The company had previously forecast $3.2 billion in profit.

Deere expects equipment sales to rise  6% this year to $35.5 billion, up from 5% previously. Analysts had expected the company to earn $8.37 a share from sales of $35.2 billion.

AFLAC Is Still a Solid Long Term Buy

aflac

aflac (Photo credit: debaird™)

fter the close last Tuesday, AFLAC (NYSE:AFL) reported fourth-quarter earnings of $1.48 per share. Make no mistake: this was a solid quarter for the duck stock, and it was squarely in line with what they told us to expect. Three months ago, AFLAC said Q4 EPS should range between $1.46 and $1.51.

But here’s the issue for us: Since most of AFLAC’s business comes from Japan, their bottom line can be adversely impacted (or helped) by fluctuations in the yen/dollar exchange rate. Lately, the government in Japan has aggressively stated its intention of pursuing a pro-inflation policy. That’s caused the yen to tank against the dollar. In response, the Nikkei Index has soared.

AFLAC as a business is fine and dandy and as strong as it’s ever been. I want to make it clear that I’m not overly worried about the exchange rate, but I have to say that it’s an issue for investors. AFLAC said the falling yen cost dinged their Q4 by four cents per share. Not fun, but not a disaster either. Bear in mind that AFLAC’s full-year earnings for 2012 were actually helped by one penny per share, thanks to the exchange rate. So it works in both directions.

For all of 2012, AFLAC made $6.60 per share in operating earnings. The company said it sees operating earnings growth of 4% to 7% for this year. On a currency-neutral basis, that means operating earnings of $6.86 to $7.06 per share.

Now here’s the tricky part (warning: math ahead). Each move in the exchange rate of one yen from 78.5 will cost AFLAC 4.3 cents per share for the year. So if the exchange rate averages 90 for the entire year, that will cost AFLAC 49.45 cents per share (11.5 times 4.3).

That stings, but it’s roughly 50 cents per share out of $7 of earnings. It’s not enough for me to change my opinion that AFLAC is a very solid stock to own. And of course, I have no idea what the exchange rate will do this year. However, I suspect that most of the damage to the yen has already been done.

Shares of AFL pulled back after the earnings report, and stand right around $50 per share as of mid-day Friday,  but the stock is basically where it was three months ago.

AFLAC remains an excellent company. Due to the recent pullback, I’m going to lower my Buy Below to $54 per share.

Gildan Activewear Inc.

Gildan Activewear

Gildan Activewear (Photo credit: Wikipedia)

GIL : NYSE : US$36.55
BUY 
Target: US$42.00

COMPANY DESCRIPTION:
Gildan is one of North America’s premier vertically integrated apparel manufacturers, focusing on frequent replenishment items with relatively low fashion risk. The company sells to the wholesale market, along with directly to retail.

RECORD RESULTS TO BEGIN F2013


Investment recommendation
We are raising our target price to US$42.00 (from US$41.00) following strong Q1/F13 earnings results.
Investment highlights
 Gildan reported Q1/F13 earnings results on Wednesday, after the market close. Revenue increased 39% YoY to $421 million, ahead of
previous guidance of $400 million. After excluding restructuring and acquisition related costs, EPS of $0.32 was ahead of consensus of $0.30 and well above Q1/F12 at -$0.38. Gildan reiterated its F2013 EPS guidance of $2.60-2.70, although we believe this has room for upward revisions as the year progresses.
 During the quarter Printwear sales grew an impressive 66% YoY to $244 million, driven by higher overall unit volumes, the nonrecurrence
of both inventory destocking and the distributor devaluation discount which occurred last year. Promotional discounting in the channel was also lower than previously anticipated. Meanwhile, Branded Apparel sales improved 13% YoY due to increased sales of Gildan branded products, which offset lower YoY sock sales.
Valuation
Our 12-month US$42.00 target price represents 15.7x our F2013 EPS estimate of $2.68. We believe there is a strong probability for upward
guidance revisions as the year progresses, should cotton prices remain range-bound, and should Gildan secure additional retail wins and
wholesale market share.

Trading Alert DRYS

China Iron Ore Imports

Baltic Freight Index Recovering

2.32USDIncrease0.14(6.42%)Volume:
Above Average
As of 29 Jan 2013 at 10:02 AM EST.

Shares of the drybulk shippers rose as higher demand for capesizes drove shipping rates up. The Baltic Exchange’s main sea freight index, which tracks rates for ships carrying dry commodities, rose for a eleventh straight day on Thursday on higher demand for capesizes. The main index, which gauges the cost of shipping commodities such as iron ore, cement, grain, coal and fertilizer, rose 39 points, or 4.99 percent, to 820 points.

Quote Details

Open 2.20 P/E Ratio (TTM)
Last Bid/Size 2.32 / 121 EPS (TTM) -0.58
Last Ask/Size 2.33 / 96 Next Earnings 27 Feb 2013
Previous Close 2.18 Beta 3.30
Volume 2,541,138 Last Dividend
Average Volume 4,383,397 Dividend Yield 0.00%
Day High 2.33 Ex-Dividend Date
Day Low 2.18 Shares Outstanding 424.8M
52 Week High 3.84 # of Floating Shares 379.1371M
52 Week Low 1.46 Short Interest as % of Float 2.29%

Apple’s Stock Looks Cheap ( Part 2)

Apple Inc.  New Headquarters

Apple Inc. New Headquarters (Photo credit: MarkGregory007)

( Read with Monday post)

Apple stock has tanked 35% from its all-time high, and now sits at $450.

If things go badly for Apple over the next several years, the stock could fall a lot farther from here.

But if things go even moderately well, the stock should deliver a compelling return.

Why?

Because, at $450, the stock looks cheap.

At $450, Apple stock is trading at 10X trailing earnings per share.

For a company that is still expected to grow, albeit at a much reduced rate, that’s an attractive valuation.

Importantly, Apple also has $135 billion of cash and no debt. Much of this cash is available to be returned to shareholders in the form of stock buybacks and, possibly, dividend increases. So it’s worth considering Apple’s market value and multiple excluding this cash.

Excluding its cash, Apple’s business is now valued at about $300 billion, or 2X revenue. Apple’s business currently earns about $40 billion a year. So Apple’s business is valued at about 7-times earnings.

That’s an even more attractive valuation. Even when you consider that Apple’s earnings are now declining.

Think about it this way.

If you spent $425 billion to buy Apple today–the whole company, not some shares of stock–you would be able to immediately pocket the $135 billion of Apple’s cash. You would then own a business that spits out about $40 billion of cash per year. Assuming the business maintains close to this level of earnings, you would get the remaining ~$300 billion of your purchase price back in about 7-10 years. You would then own all of Apple and its future earnings “for free.”

Even if Apple’s earnings shrink over the next few years–which I actually think is likely (Apple’s net income in the next quarter is expected to be down a startling 20% from last year)–it would only take 10-15 years for you to get your money back.

If Apple’s earnings grew instead of stayed flat, meanwhile–which isn’t inconceivable–you would get your money back even faster than 7 years.

In other words, unless Apple’s earnings really tank, and stay down, you will have bought a good company at a reasonable price.

Now, you are not going to be buying all of Apple anytime soon, so you can only think about the description above theoretically. But here is a more likely scenario.

A more likely scenario is that Apple’s earnings will stay flat or drop over the next several years, and Apple will start to get even more serious about returning some of its massive cash pile to investors.

To reiterate: Apple has ~$135 billion of cash.

And it is currently generating more cash at a rate of about ~$40 billion per year.

Apple has no idea what to do with this money.

No company needs $135 billion of cash.

In the past, Apple has demonstrated that it is not stupid enough to make huge, bad acquisitions (at least so far). So one can hope that Apple will not be stupid enough to make such acquisitions going forward.

So that leaves two other ways to use the cash mountain that Apple continues to pile up and doesn’t know what to do with:

Right now, Apple pays a ~$10 annual dividend. With the stock at $450, that’s about a 2.5% yield.

Paying this dividend costs Apple about $10 billion of cash per year.

Apple could easily afford to double this dividend to ~$20 per year.

That would create a 5% yield, which is an excellent yield. It’s also a much higher yield than almost every other stock in the market pays. And even this would only consume $20 billion a year.

And Apple could also easily afford to spend another $20 billion a year buying back its own stock. At $450 a share, this would shrink the share base by about 5% per year. So Apple’s earnings would be split up over fewer shares.

If Apple keeps earning $40 billion a year, and it returns $40 billion a year to shareholders, its cash balance will stay at ~$135 billion, which, again, is vastly more cash than it needs.

Apple could use $50-$100 billion of that cash to buy back stock, and that would shrink the share base even further.

All of which is to say, Apple has multiple levers at its disposal to return cash to shareholders and boost earnings per share irrespective of the business. And the business itself looks cheap relative to its current earnings stream.

Now, I am not suggesting that Apple’s stock is suddenly going to rocket back to $700. For that to happen, Apple would have to release another product that is a quantum leap over the competition, and it would have to sell hundreds of millions of units of this product before its competitors caught up. (As has happened with the iPhone).

I am also not suggesting that Apple’s stock won’t go lower from here. It may very well go lower from here. In fact, it may go lower and stay lower–forever.

As I described a few days before Apple missed Q4 expectations and the stock crashed below $500, Apple could be in the beginning stages of the same sort of implosion that it experienced in the 1990s–the same sort of implosion that has claimed Research In Motion, Palm, Nokia, Yahoo, AOL, Cisco, and dozens of other tech giants over the years. The stocks of these companies are trading at mere fractions of the highs they hit back when they were “must-own” stocks, barring miracles, they will never trade at those highs again. Apple is certainly not immune from this fate. And anyone who still thinks it is is not facing up to the reality of the situation.

But, Apple is also still a good company. And it has good products in fast-growing markets–smartphones and tablets. So if it can merely remain a good company, and keep pace with the competition (again, no guarantees), and if it begins to return even more of its vast cash mountain to shareholders, it should be able to maintain strong earnings per share, at least for a while.

And if Apple can do that, the stock doesn’t just look cheap. It is cheap.

As a reminder, no one knows what is going to happen to Apple over the next few years, including the folks at Apple. So don’t hallucinate that there’s some guru somewhere who can tell you. All of these scenarios are possible, including the “train-wreck” one. Stock prices represent collective guesses about what will happen in the future, and no one knows for sure what the future holds.

One final caveat…

Most of the folks who bought Apple stock over the past 5 years bought it because they considered it a “growth” stock, not a “value” stock. The scenario I described above is very much a “value” stock scenario. If Apple’s earnings do decline over the next couple of years, the “growth” investors who bought Apple’s stock will jettison it, and the “value” investors will have to buy it. This process will take time. So even if Apple does end up delivering a compelling return over the next few years, this “turnaround” will likely take a while.

Google Q4 Preview

Image representing Google as depicted in Crunc...

Image via CrunchBase

Google

GOOG : NASDAQ : US$724.93
BUY  Target: US$810.00

COMPANY DESCRIPTION:
Google owns the world’s largest search engine, some of the most visited websites on the web, including YouTube.com, as well as the  telecommunications equipment corporation Motorola Mobility. Google generates the vast majority of its revenue through advertising on the web and mobile devices.

Q4 PREVIEW: TRIMMING 2013 & 2014 ON KEY MODEL DYNAMICS
Summary
Google reports Q4 results on Tuesday, January 22. We believe expectations are largely reasonable, although we note there are more moving parts than normal in the model (the basis for our 2013-14 revisions) that could add to volatility around earnings.
Key Points
 We are trimming estimates for 2013 and 2014 based on

1) nearterm PLA dynamics,

2) Nexus-related gross margin dilution,

3) ongoing TAC escalation, and

4) lower MMI estimates.

Our new 2013 revenue and EPS estimates are $62.8 billion/$46.37, down from $64.9 billion/$50.57.
 Of note, we believe that Google gross margin, which should continue to trend lower for a few quarters, should have a good chance of
bottoming around Q3, as we forecast Nexus subsidies can shift from headwind to tailwind, more than offsetting what we see as a continued climb in TAC (and we introduce a working framework for forecasting TAC mix within).
Valuation
Our $810 price target is unchanged and is based on 17.5x our revised 2013 EPS estimate of $46.37.

GOLDMAN SACHS: How To MAKE A Killing In The Stock Market In 2013

goldman sachs

goldman sachs (Photo credit: alyceobvious)

The call made by David Kostin is for the S&P to gain 12% from here, anding 2013 at 1575. If you add in dividends, the gain is 14%.

So if you just buy the S&P 500, you should do pretty fantastic next year.

Why is Kostin so bullish?

The firm sees 2013 growth GDP growth of about 2%, S&P revenue growth of 4.4%, margins staying flat where they are, and S&P earnings of $107 (up from $100).  After we get past the fiscal cliff, S&P multiples will expand modestly by about 5%.

So how can you do even better than the 12%?

Kostin suggests a few different avenues.

  • Bet on cyclicals (like materials and tech) over defensives (like healthcare and consumer staples).
  • Stocks that have experienced both high-risk adjusted EPS growth and risk-adjusted actual growth.
  • Bet on BRICs exposure over domestic exposure.

This last point is particularly interesting. One of the big themes of 2012 has been the outperformance of US exposure vs. foreign exposure.

Now Goldman sees this reversing. Growth is expected to bounce back, and Goldman is above consensus in its BRICs growth estimates.

And Goldman isn’t alone.

In BofA/ML’s equity outlook, it also sees a return to over-performance among companies with foreign exposure.

foreign exposure

BofA/ML

Bottom line from Goldman: Buy stocks, buy BRICs, and cyclicals.

This is a very bullish outlook.

Follow

Get every new post delivered to your Inbox.

Join 1,174 other followers